Evaluation of Primaquine Pharmacokinetics in the patients of P.vivax and P.falciparum malaria.

il0 个研究点目标入组 50 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Patients with confirmed cases of vivax and falciparum malaria (asexual forms) by microscopy on a thin blood smear (parasite density >300/mm3)
•-Patients giving written informed consent to participate in this study.
•-Male and female patients aged 18 -65 years.
•-Patients with axillary temperature >37.50C (>99.50F)
•-Patients with chills, nausea, vomiting, headache, malaiase and any 2 of the following signs/symptoms of uncomplicated malaria (diarrhea, anorexia, abdominal cramps, myalgia, arthralgia)
•-Normal G-6-P-D status as assessed by qualitative and quantitative tests.

•-Patients with history of hypersensitivity to chloroquine, quinine, primaquine or aminoquinoline derivatives or other similar drugs as assessed by history.
•-Pregnant (female patients with prescribed pregnancy test positive) or lactating women.
•-Patients with severe or complicated malaria or mixed malarial infection.
•-Patients taking cardioactive drug or potentially hemolytic drugs or bone marrow depressants.
•-Patients on another investigational drug.
•-Patients with concomitant illness (cardiac, hepatic or renal diseases)
•-Patients previously treated with any other antimalarial therapy except chloroquine
•-Patients with glucose 6-phosphate dehydrogenase deficiency

发起方